Safety Study of MT-4666 in Subjects With Alzheimer's Disease
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666
administered once daily for 52 weeks with or without receiving a concomitant
acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's
Disease (AD).